CA3236793A1 - N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors - Google Patents
N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors Download PDFInfo
- Publication number
- CA3236793A1 CA3236793A1 CA3236793A CA3236793A CA3236793A1 CA 3236793 A1 CA3236793 A1 CA 3236793A1 CA 3236793 A CA3236793 A CA 3236793A CA 3236793 A CA3236793 A CA 3236793A CA 3236793 A1 CA3236793 A1 CA 3236793A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- imidazol
- mmol
- carboxamide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202116077 | 2021-11-09 | ||
| GB2116077.5 | 2021-11-09 | ||
| PCT/GB2022/052833 WO2023084206A1 (en) | 2021-11-09 | 2022-11-09 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3236793A1 true CA3236793A1 (en) | 2023-05-19 |
Family
ID=84360092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3236793A Pending CA3236793A1 (en) | 2021-11-09 | 2022-11-09 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250019369A1 (https=) |
| EP (1) | EP4430034A1 (https=) |
| JP (1) | JP2024540318A (https=) |
| CN (1) | CN118317955A (https=) |
| CA (1) | CA3236793A1 (https=) |
| WO (1) | WO2023084206A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023235880A1 (en) * | 2022-06-02 | 2023-12-07 | Aeovian Pharmaceuticals, Inc. | Cd38 modulators and uses thereof |
| AU2024285368A1 (en) * | 2023-06-07 | 2025-12-18 | Flagship Pioneering Innovations Vi, Llc | Condensed azines as inhibitors of cyclic adp ribose hydrolase |
| WO2026000074A1 (en) * | 2024-06-25 | 2026-01-02 | Welnx Company Inc. | Use of cd38 inhibitors for reducing th2 inflammation |
| WO2026075971A1 (en) | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021021986A1 (en) | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
| BR112022020291A2 (pt) * | 2020-04-07 | 2022-12-06 | Mitobridge Inc | Inibidores de cd38 |
| US20240254113A1 (en) * | 2021-04-30 | 2024-08-01 | Nanjing Immunophage Biotech Co., Ltd. | Compounds and their uses as cd38 inhibitors |
-
2022
- 2022-11-09 CA CA3236793A patent/CA3236793A1/en active Pending
- 2022-11-09 EP EP22805932.5A patent/EP4430034A1/en active Pending
- 2022-11-09 JP JP2024526654A patent/JP2024540318A/ja active Pending
- 2022-11-09 US US18/708,486 patent/US20250019369A1/en active Pending
- 2022-11-09 WO PCT/GB2022/052833 patent/WO2023084206A1/en not_active Ceased
- 2022-11-09 CN CN202280073666.2A patent/CN118317955A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024540318A (ja) | 2024-10-31 |
| CN118317955A (zh) | 2024-07-09 |
| US20250019369A1 (en) | 2025-01-16 |
| EP4430034A1 (en) | 2024-09-18 |
| WO2023084206A1 (en) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3236793A1 (en) | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors | |
| AU2020394444B2 (en) | Substituted macrocyclic compounds and related methods of treatment | |
| AU2016256917B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| CA2930754C (en) | Pyrazolopyridine derivatives as modulators of tnf activity | |
| CA2481482C (en) | Tropane derivatives as ccr5 modulators | |
| JP2022521536A (ja) | イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用 | |
| AU2016258188B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| US20210078971A1 (en) | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| AU2005262330A1 (en) | Piperidine derivatives as NK1 antagonists | |
| CA3128421C (en) | Janus Kinase (JAK) Family Inhibitor, its Preparation and Applications | |
| JP2025541981A (ja) | 縮合多環式化合物及びｐａｒｐ１阻害剤としてのそれらの使用 | |
| JP7592069B2 (ja) | 抗マラリア性ヘキサヒドロピリミジン類似体 | |
| KR20230117460A (ko) | 신규한 lrrk2 억제제 | |
| EP4713323A1 (en) | 3-carbonyl imidazo[1,5-a]pyridine derivatives for use as cd38 inhibitors for the treatment of cns disorders | |
| EP4713322A1 (en) | 1,3-thiazole and 1,2,4-thiadiazole derivatives for use as cd38 inhibitors for the treatment of cns disorders | |
| AU2019218256A1 (en) | Heterocyclic P2Y14 receptor antagonists | |
| TW202529754A (zh) | Tyk2抑制劑及其用途 | |
| EP4421077A1 (en) | Aryl or heteroaryl derivative, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of kinase-related diseases | |
| WO2023023670A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| JP2024532729A (ja) | フェロトーシス調節物質、その調製及び使用 | |
| WO2023227867A1 (en) | Heterobicyclic amides as inhibitors of cd38 | |
| JP2006511528A (ja) | Ｎｒ２ｂレセプターアンタゴニストとしての２−ピリジル及び２−ピリミジルシクロアルキレンアミド化合物 | |
| WO2024121183A1 (en) | New cyanopyridine khk inhibitor compounds | |
| WO2024158653A2 (en) | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background | |
| WO2025243042A1 (en) | Compounds for the inhibition of cyclophilin d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241104 |